Ariad to resume sale of leukemia drug Iclusig

Fri Dec 20, 2013 10:26am EST

Dec 20 (Reuters) - Ariad Pharmaceuticals Inc said it will resume selling its leukemia drug, Iclusig, in the United States, nearly two months after sales were halted due to safety concerns.

The U.S. Food and Drug Administration approved a revised label for the drug including a boxed warning, updated safety information and recommendations regarding dosing.

Ariad shares jumped 26 percent to $6.96 in heavy volume trading on Friday.

(Reporting by Esha Dey in Bangalore)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.